title: Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.
abstract: In this study, the effects were examined of dose and adjuvant of whole-killed gp120-depleted HIV-1 antigen on antibody and cytokine responses in a murine model. Immunization with increasing doses of inactivated HIV-1 antigen in Incomplete Freund's Adjuvant (IFA) resulted in increased production of IL-4 and IgG1 antibody with decreased production of interferon gamma. Immunization with inactivated HIV-1 antigen in Detox PC adjuvant produced TH1 type predominant cytokine patterns along with IgG2a subclass antibody. Higher levels of interferon gamma were associated with immunization with inactivated HIV-1 antigen in Detox PC compared with inactivated HIV-1 in IFA or inactivated HIV-1 in saline. Inactivated HIV-1 antigen in Detox PC adjuvant produced a trend of lower levels of the beta-chemokine MIP-1 alpha compared with inactivated HIV-1 in IFA or saline. Dose and adjuvant play an important role in the type of immune response elicited to a whole-killed HIV vaccine. Low doses of inactivated HIV-1 antigen in Detox PC adjuvant are currently being studied in animal models in order to optimize cell-mediated immunity against HIV infection.
authors.affiliation: Immune Response Corporation, Carlsbad, CA 92008, USA.
authors.forename: P
authors.initials: P
authors.lastname: Lanza
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: W
authors.initials: W
authors.lastname: Giermakowska
authors.forename: R B
authors.initials: RB
authors.lastname: Hancock
authors.forename: S P
authors.initials: SP
authors.lastname: Richieri
authors.forename: G
authors.initials: G
authors.lastname: Theofa
authors.forename: F C
authors.initials: FC
authors.lastname: Jensen
authors.forename: P L
authors.initials: PL
authors.lastname: Salk
authors.forename: D J
authors.initials: DJ
authors.lastname: Carlo
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000494:pharmacology*; D000818:Animals; D054407:Chemokine CCL4; D004305:Dose-Response Relationship, Drug; D005620:Freund's Adjuvant / Q000276:immunology / Q000494:pharmacology*; D015483:HIV Antibodies / Q000096:biosynthesis; D015488:HIV Antigens / Q000276:immunology* / Q000494:pharmacology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control*; D007074:Immunoglobulin G / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D015847:Interleukin-4 / Q000096:biosynthesis / Q000276:immunology; D019402:Macrophage Inflammatory Proteins / Q000096:biosynthesis / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D015164:Vaccines, Inactivated / Q000276:immunology / Q000494:pharmacology
chemical_list: D016915:AIDS Vaccines; D054407:Chemokine CCL4; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D007074:Immunoglobulin G; D019402:Macrophage Inflammatory Proteins; D015164:Vaccines, Inactivated; D015847:Interleukin-4; D007371:Interferon-gamma; D005620:Freund's Adjuvant